Diabetes mellitus type 2 future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There are some limited data supporting [[Cannabis (drug)|cannabis]] as a potential therapeutic agent for [[diabetes mellitus type 2]]. These studies suggest that there is a relationship between [[cannabinoids]] and lower rate of [[obesity]] and [[diabetes mellitus type 2]]. Since these data are restricted, more study is required regards this potential therapy. | There are some limited data supporting [[Cannabis (drug)|cannabis]] as a potential therapeutic agent for [[diabetes mellitus type 2]]. These studies suggest that there is a relationship between [[cannabinoids]] and lower rate of [[obesity]] and [[diabetes mellitus type 2]]. Since these data are restricted, more study is required regards this potential [[therapy]]. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
* A [[Randomized controlled trial|randomized]], [[Blind experiment|double-blind]], [[Placebo-controlled studies|placebo-controlled]] study done on [[Diabetes mellitus type 2|type 2 diabetic]] patients with [[Cannabis (drug)|cannabis]] use showed possible [[therapeutic effect]] on [[diabetes mellitus type 2]]. Δ(9)-[[tetrahydrocannabivarin]] ([[Tetrahydrocannabivarin|THCV]]) in [[Cannabis (drug)|cannabis]] was related to lower [[Blood sugar|fasting blood sugar]] (FBS), better [[Beta cell|pancreatic beta cell]] function, improved [[adiponectin]] and [[Apolipoprotein A1|apolipoprotein A]], compared to [[placebo]] group. On the contrary, [[Tetrahydrocannabivarin|THCV]] had not any effect on [[High density lipoprotein|HDL cholesterol]].<ref name="pmid27573936">{{cite journal| author=Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD | display-authors=etal| title=Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. | journal=Diabetes Care | year= 2016 | volume= 39 | issue= 10 | pages= 1777-86 | pmid=27573936 | doi=10.2337/dc16-0650 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27573936 }}</ref> | * A [[Randomized controlled trial|randomized]], [[Blind experiment|double-blind]], [[Placebo-controlled studies|placebo-controlled]] study done on [[Diabetes mellitus type 2|type 2 diabetic]] patients with [[Cannabis (drug)|cannabis]] use showed possible [[therapeutic effect]] on [[diabetes mellitus type 2]]. Δ(9)-[[tetrahydrocannabivarin]] ([[Tetrahydrocannabivarin|THCV]]) in [[Cannabis (drug)|cannabis]] was related to lower [[Blood sugar|fasting blood sugar]] ([[Blood sugar|FBS]]), better [[Beta cell|pancreatic beta cell]] function, improved [[adiponectin]] and [[Apolipoprotein A1|apolipoprotein A]], compared to [[placebo]] group. On the contrary, [[Tetrahydrocannabivarin|THCV]] had not any effect on [[High density lipoprotein|HDL cholesterol]].<ref name="pmid27573936">{{cite journal| author=Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD | display-authors=etal| title=Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. | journal=Diabetes Care | year= 2016 | volume= 39 | issue= 10 | pages= 1777-86 | pmid=27573936 | doi=10.2337/dc16-0650 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27573936 }}</ref> | ||
* Another study that investigated 579 of current [[Cannabis (drug)|cannabis]] users and 1975 of previous [[Cannabis (drug)|cannabis]] users, concluded that [[Cannabis (drug)|cannabis]] use is related to lower level of [[insulin]] in fasting state, lower Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and smaller waist circumference.<ref name="pmid23684393">{{cite journal| author=Penner EA, Buettner H, Mittleman MA| title=The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. | journal=Am J Med | year= 2013 | volume= 126 | issue= 7 | pages= 583-9 | pmid=23684393 | doi=10.1016/j.amjmed.2013.03.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23684393 }}</ref> | * Another study that investigated 579 of current [[Cannabis (drug)|cannabis]] users and 1975 of previous [[Cannabis (drug)|cannabis]] users, concluded that [[Cannabis (drug)|cannabis]] use is related to lower level of [[insulin]] in fasting state, lower Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and smaller waist circumference.<ref name="pmid23684393">{{cite journal| author=Penner EA, Buettner H, Mittleman MA| title=The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. | journal=Am J Med | year= 2013 | volume= 126 | issue= 7 | pages= 583-9 | pmid=23684393 | doi=10.1016/j.amjmed.2013.03.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23684393 }}</ref> | ||
Latest revision as of 14:44, 17 August 2020
Diabetes mellitus type 2 Microchapters |
Differentiating Diabetes Mellitus Type 2 from other Diseases |
Diagnosis |
Treatment |
Medical therapy |
Diabetes mellitus Main page |
Patient Information |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
There are some limited data supporting cannabis as a potential therapeutic agent for diabetes mellitus type 2. These studies suggest that there is a relationship between cannabinoids and lower rate of obesity and diabetes mellitus type 2. Since these data are restricted, more study is required regards this potential therapy.
Future or Investigational Therapies
- A randomized, double-blind, placebo-controlled study done on type 2 diabetic patients with cannabis use showed possible therapeutic effect on diabetes mellitus type 2. Δ(9)-tetrahydrocannabivarin (THCV) in cannabis was related to lower fasting blood sugar (FBS), better pancreatic beta cell function, improved adiponectin and apolipoprotein A, compared to placebo group. On the contrary, THCV had not any effect on HDL cholesterol.[1]
- Another study that investigated 579 of current cannabis users and 1975 of previous cannabis users, concluded that cannabis use is related to lower level of insulin in fasting state, lower Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and smaller waist circumference.[2]
References
- ↑ Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD; et al. (2016). "Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study". Diabetes Care. 39 (10): 1777–86. doi:10.2337/dc16-0650. PMID 27573936.
- ↑ Penner EA, Buettner H, Mittleman MA (2013). "The impact of marijuana use on glucose, insulin, and insulin resistance among US adults". Am J Med. 126 (7): 583–9. doi:10.1016/j.amjmed.2013.03.002. PMID 23684393.